CLSA has an outperform rating on Bharti Airtel with the target price at Rs 2,320, up marginally from Rs 2,310 earlier. Analysts said Bharti Airtel is accelerating investments in data centre subsidiary Nxtra Data to $1 billion. Nxtra will ramp up capacity from 300MW to 1GW targeting a 25% market share. Bharti will retain a controlling stake post the deal, which values Nxtra at $3.1 billion. Nxtra’s business is co-location with a pan-India network of 14 large and 120+ edge data centres. Nxtra’s FY25 revenue and earnings before interest, taxes, depreciation and amortisation (EBITDA) were Rs 2,080 crore and Rs 790 crore, respectively, with net profit at Rs 220 crore.Morgan Stanley has an overweight rating on Jubilant Foodworks with the target price at Rs 690. Analysts said the company decided to not renew the Dunkin brand franchise agreement. Dunkin’s operations contributed merely 0.6% of the company revenues and was a loss making one. The closure of this part of the operation will not have any material financial implications on the company. Analysts saw the decision positively and they liked the management’s strategic focus on scaling the core Dominos brand and selecting new brands like Popeyes.Jefferies has a buy rating on Interglobe Aviation (Indigo) with the target price at Rs 6,150. Analysts said Indigo has appointed Willie Walsh as CEO, starting in early-Aug following his IATA tenure. With a 40-year experience in aviation, including leading British Airways through crises, Walsh brings global expertise amid Indigo’s growth phase, operational stabilization and international expansion. Walsh came in just three weeks after Pieter Elbers’ resignation, which minimizes leadership gaps. For the airline, the priorities from here might include reliability, crew issues, and balancing low-cost model amid recent cost headwinds.Nomura has a buy rating on Nephrocare Health Services with the target price at Rs 605. Analysts said the company’s dialysis services are sticky and scalable, with the market dominated by a few players. NephroPlus is well positioned to prevail in the emerging markets. The company has a single-speciality healthcare service with a recurring-revenue potential. There’s a strong growth opportunity for large, organized players in emerging economies.Investec has a buy rating on RateGain Travel with the target price at Rs 775. Analysts said RateGain (RG) is a differentiated travel-tech platform that provides Data-as-a-Service (DaaS), distribution, and marketing technology solutions to hotels, OTAs, destination marketing organizations to help them maximize revenue. Three things stand out for the company. Firstly, the company’s integrated capability stack is unmatched in the industry. The potential impact from AI-led disruption on the company’s business is minimal. And lastly, RateGain needs to execute at speed to maintain moat and strategic advantage.(Disclaimer: Recommendations and views on the stock market, other asset classes or personal finance management tips given by experts are their own. These opinions do not represent the views of The Times of India)
